UNSPSC 51433504: Phenactropinium

This classification denotes a nicotinic antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43P9Q83UFF. European Medicines Agency schedules Phenactropinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09746MIG. Phenactropinium generally arises in the molecular formula C24H28NO4.CL.

The term PHENACTROPINIUM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) As of Q4 2014, PHENACTROPINIUM remains the US FDA Preferred Term for this commodity. SMILES: C[N+]1(C2CCC1CC(C2)OC(=O)C(C3=CC=CC=C3)O)CC(=O)C4=CC=CC=C4.

UNSPSC 51433504 Phenactropinium is a Commodity code that covers specific pharmaceutical active ingredients and chemical compounds used in emergency medical care, hospital formularies, and state health programs. State and local governments procure phenactropinium primarily as a component within Advanced Life Support medications and as part of broader pharmaceutical supply contracts managed through cooperative purchasing alliances and individual health system procurement departments. The issuing bodies include city fire departments (through purchasing departments), state health and human services commissions, and multistate cooperative purchasing organizations that aggregate demand across participating state and local jurisdictions. Scope of work centers on supply of pharmaceutical-grade compounds meeting FDA requirements, expiration-date specifications, storage and handling compliance with OSHA Hazard Communication Standards, and delivery guarantees tied to emergency response timelines.

Recent activity spans Florida, Texas, and a multistate cooperative footprint including Minnesota and Oregon. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (response deadline April 8, 2026), soliciting phenactropinium-containing compounds alongside epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year initial term plus renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026 deadline) to gather vendor capabilities for direct-to-manufacturer prescription programs that would include pharmaceutical ingredients outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 (March 26, 2026 deadline) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendor compliance with cGMP, Drug Supply Chain Security Act certification, and relationships with authorized wholesalers. Contract values in cooperative purchasing arrangements are not disclosed upfront; vendors must absorb a 3 percent administrative fee and accept performance penalties ranging from $200 to $1,500 per violation.